Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Foghorn Therapeutics discovers SMARCA2/SMARCA4 inhibitors

Aug. 27, 2021

XRad initiates phase Ia study of XRD-0394 with radiation therapy in advanced solid tumors

Aug. 27, 2021

CPI-613 advances into phase II evaluation in biliary tract cancer

Aug. 26, 2021

New phase I/II trial investigates RVU-120 in relapsed/refractory metastatic or advanced solid tumors

Aug. 26, 2021

HUTCHMED begins phase Ib/II study of fruquintinib with tislelizumab in TNBC and endometrial cancer

Aug. 26, 2021

Janssen targets DHODH with new compounds for acute myelogenous leukemia

Aug. 26, 2021

New Toll-like receptor 7 agonists identified at Bristol Myers Squibb

Aug. 26, 2021

Bio-Path receives IND clearance for phase I/Ib study of BP-1002 in relapsed or refractory AML

Aug. 25, 2021

Incyte discovers GTPase KRAS mutant inhibitors

Aug. 25, 2021

Zhejiang Hisun Pharmaceutical patents TYK2/JAK-1/JAK-2/JAK-3 inhibitors

Aug. 25, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.